Payment overview · 2025
General Payments
$760.38
31 reported records · 15 companies
Healthcare provider profile · identity verified
Kay Kelts, DO
Allopathic & Osteopathic Physicians|Family Medicine · RAPID CITY, SD · NPI 1083956932
Verified facts
What the public records show
CMS Open Payments records show Kay Kelts, DO received $760.38 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $225.20 | 29.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $93.45 | 12.3% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $85.67 | 11.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $66.55 | 8.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.81 | 6.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.18 | 4.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $35.01 | 4.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $32.46 | 4.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.36 | 3.7% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.39 | 3.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.35 | 2.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.74 | 2.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.50 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.18 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.53 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $760.38 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $225.20 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $86.22 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $86.22 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $85.67 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $71.32 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $71.32 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $66.55 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $32.46 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.36 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.36 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.39 | 1 | 2025 |
Source payment records
|
|||||
| LILETTA Normalized: liletta |
Drug | ABBVIE INC. | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 85 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
147 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 506 | 127 |
| Atorvastatin Calcium | Atorvastatin Calcium | 480 | 125 |
| Losartan Potassium | Losartan Potassium | 405 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 333 | 85 |
| Omeprazole | Omeprazole | 330 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 284 | 81 |
| Simvastatin | Simvastatin | 212 | 50 |
| Lisinopril | Lisinopril | 209 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 199 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 185 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 44 |
| Mounjaro | Tirzepatide | 147 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 38 |
| Tramadol Hcl | Tramadol Hcl | 134 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 133 | 35 |
| Gabapentin | Gabapentin | 130 | 33 |
| Potassium Chloride | Potassium Chloride | 130 | 34 |
| Furosemide | Furosemide | 123 | 38 |
| Meloxicam | Meloxicam | 119 | 37 |
| Metformin Hcl | Metformin Hcl | 100 | 27 |
| Alprazolam | Alprazolam | 92 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 87 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 19 |
| Eliquis | Apixaban | 85 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 16 |
| Trazodone Hcl | Trazodone Hcl | 73 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 20 |
| Metformin Hcl Er | Metformin Hcl | 67 | 21 |
| Spironolactone | Spironolactone | 67 | 20 |
| Pregabalin | Pregabalin | 65 | 20 |
| Montelukast Sodium | Montelukast Sodium | 62 | 15 |
| Topiramate | Topiramate | 62 | 23 |
| Synthroid | Levothyroxine Sodium | 61 | 17 |
| Bupropion Xl | Bupropion Hcl | 60 | 20 |
| Carvedilol | Carvedilol | 58 | 17 |
| Ezetimibe | Ezetimibe | 57 | 20 |
| Famotidine | Famotidine | 56 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 21 |
| Donepezil Hcl | Donepezil Hcl | 53 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 15 |
| Allopurinol | Allopurinol | 51 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 11 |
| Estradiol | Estradiol | 49 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 19 |
| Clonazepam | Clonazepam | 46 | 13 |
| Magnesium Sulfate | Magnesium Sulfate | 46 | suppressed |
| Celecoxib | Celecoxib | 44 | 15 |
| Baclofen | Baclofen | 43 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | 11 |
| Cephalexin | Cephalexin | 40 | 20 |
| Prednisone | Prednisone | 39 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 15 |
| Ozempic | Semaglutide | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Mirtazapine | Mirtazapine | 35 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Dutasteride | Dutasteride | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Olanzapine | Olanzapine | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Armour Thyroid | Thyroid,pork | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Naltrexone Hcl | Naltrexone Hcl | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $760.38 · 31 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, ELIQUIS, ENTRESTO, EVENITY, FARXIGA, INSPIRE, JARDIANCE, Kerendia, LEQVIO, LILETTA, MINIMED 780G, NURTEC ODT, Ozempic, PREVNAR 20, PROLIA, QULIPTA, Rybelsus, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, Veozah, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error